Citadel Advisors’s Akoya BioSciences AKYA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-17,900
| Closed | -$24.9K | – | 12369 |
|
|
2025
Q1 | $24.9K | Sell |
17,900
-100
| -0.6% | -$219 | ﹤0.01% | 12981 |
|
|
2024
Q4 | $41.2K | Sell |
18,000
-6,100
| -25% | -$16.2K | ﹤0.01% | 12586 |
|
|
2024
Q3 | $65.6K | Buy |
24,100
+17,500
| +265% | +$42.7K | ﹤0.01% | 11624 |
|
|
2024
Q2 | $15.4K | Sell |
6,600
-1,400
| -18% | -$4.46K | ﹤0.01% | 12831 |
|
|
2024
Q1 | $37.5K | Sell |
8,000
-1,200
| -13% | -$6.23K | ﹤0.01% | 12462 |
|
|
2023
Q4 | $44.9K | Sell |
9,200
-900
| -9% | -$3.74K | ﹤0.01% | 11896 |
|
|
2023
Q3 | $47K | Sell |
10,100
-3,600
| -26% | -$20.7K | ﹤0.01% | 11831 |
|
|
2023
Q2 | $101K | Sell |
13,700
-3,900
| -22% | -$26K | ﹤0.01% | 10916 |
|
|
2023
Q1 | $144K | Buy |
17,600
+8,000
| +83% | +$83.6K | ﹤0.01% | 10705 |
|
|
2022
Q4 | $91.9K | Buy |
+9,600
| New | +$118K | ﹤0.01% | 11338 |
|
|
2022
Q3 | – | Sell |
-11,300
| Closed | -$145K | – | 12521 |
|
|
2022
Q2 | $145K | Buy |
+11,300
| New | +$117K | ﹤0.01% | 11013 |
|
Citadel Advisors's AKYA Position: Q3 2025 in Review
Citadel Advisors sold out of Akoya BioSciences (AKYA) in Q3 2025, closing a stake of 100,467 shares — an estimated $131K sold.
Citadel Advisors first reported a position in AKYA in Q2 2021 and held it in 14 quarters. The position peaked at $1.33M in Q4 2022. 0 funds tracked by Wall St. Rank hold AKYA as of Q3 2025.
- Citadel Advisors reported no remaining Akoya BioSciences position as of Q3 2025 after selling out during the quarter.
- Citadel Advisors sold 100,467 Akoya BioSciences shares in Q3 2025, an estimated $131K.
- Citadel Advisors first reported a position in Akoya BioSciences in Q2 2021 and held it in 14 quarters.
- Citadel Advisors's Akoya BioSciences position peaked at $1.33M in Q4 2022.
- 0 funds tracked by Wall St. Rank held Akoya BioSciences as of Q3 2025.
Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.